Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Clostridium difficile infection (CDI ... with positive samples then confirmed using a toxin(s) test, to distinguish toxinogenic from nontoxinogenic CDI. Although metronidazole and vancomycin ...

Li S, Shi L, Yang Z, Zhang Y, Perez-Cordon G, Huang T, Ramsey J, Oezguen N, Savidge TC, Feng H. Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis. Infect Immun. 2015 ...

Hypoxia-inducible factor (HIF) signaling protects the intestinal mucosa from injury induced by Clostridium difficile toxins, according to the results of a study published in Gastroenterology.

Purpose: Current and future treatment modalities for Clostridium difficile-associated disease (CDAD) are reviewed. Conclusion: CDAD is a major concern for health care systems and clinicians.

Bezlotoxumab, an IgG1 monoclonal antibody that targets C. difficile toxin B, is recommended for high-risk patients to help prevent additional recurrences. Although bezlotoxumab has proven ...

A group of gut bacteria successfully hindered recurrent Clostridium difficile infection in mice, offering alternative therapeutic strategies to antibiotics and fecal transplant. To investigate whether ...

Experts have met to discuss the risks and knowledge gaps around Clostridium botulinum and Clostridium perfringens. At a Food and Agriculture Organization ...